Grow bone with the *new* MagnetOs™ MIS:

Engineered for precise delivery and predictable fusions

If you're tired of making sacrifices in Minimally Invasive Surgery (MIS), we've got just the solution. The new MagnetOs MIS not only enables graft placement three times faster than traditional, funnel-based delivery methods, it also delivers predictable fusions for your patients – all supported by high-quality clinical evidence.[1,2]

At Kuros Biosciences, we've heard you loud and clear – and we've delivered: in the form of MagnetOs MIS. This single-use and prefilled MIS delivery system is designed to maximize speed and efficiency in the operating room, without compromising the ability to grow bone.[2]

MAGNETOS™
for predictable fusions

Kuros Biosciences



Grow bone
with **MagnetOs**™

The 'perfect pair' challenge: A bone graft that grows bone, with delivery that keeps you moving

We know that placing bone graft in MIS procedures represents a unique challenge for surgeons.

Limited access during a procedure demands precision and efficiency. Yet, traditional methods can be cumbersome and time-consuming, and bone grafts may lack Level I human clinical data and evidence-based outcomes.

Our solution: Introducing MagnetOs MIS

An easy-to-use solution that overcomes the challenges of traditional MIS bone graft delivery – while bringing benefits to both surgeons and hospital systems alike.

MagnetOs MIS is a precise and reliable system that easily delivers an evidence-backed bone graft for minimally invasive spinal procedures.[1]

Built on the proven science of MagnetOs and its unique NeedleGrip™ submicron surface technology which harnesses the immune system and stimulates bone growth, this advanced bone graft delivers predictable fusions.*[1,3,4] But it also enhances operational efficiency and reduces preparation challenges, allowing you to keep your focus where it belongs – on your patient.[2]

Kuros Biosciences

Proven benefits of MagnetOs: Delivering more for MIS

Our latest solution is ideally suited to MIS procedures while featuring the foundational qualities of MagnetOs.

Optimal handling

MagnetOs delivers handling qualities tailored to your needs – ready-to-use and reliably stays put.[5]

Clinical evidence

In a Level I human clinical study published in *Spine*, MagnetOs achieved nearly twice the fusion rate of autograft in posterolateral fusions (79% vs 47%). Among active smokers – who made up 1 in 5 patients – the fusion difference was even more dramatic (74% vs 30%).†‡[1,6]

Proprietary technology

MagnetOs grows bone on its own thanks to NeedleGrip technology – a proprietary submicron surface that harnesses the immune system to stimulate bone growth without added cells or growth factors.*§[3,4,7-11]

Trusted safety

MagnetOs contains no human cells or growth factors and carries no intrinsic risk of human tissue-related disease transmission.[7-11]

Broad indications

MagnetOs MIS is FDA-cleared throughout the spine (including any interbody), pelvis and extremities, and may be used standalone or mixed with autograft.¶[11]

MagnetOs MIS:
Extending your reach in minimally invasive procedures

With MagnetOs MIS, we've extended our portfolio to deliver the consistency and quality that surgeons expect from MagnetOs. But this bone graft delivery system also extends your own surgical reach.

Always ready when you are

- MagnetOs MIS is a sterile, single-use delivery system – eliminating hospital reprocessing costs and minimizing contamination risk
- No preparation needed with a 5cc prefilled cartridge of MagnetOs – 185mm length, 6mm inner and 8mm outer diameter
- No refrigeration or thawing required – stored at ambient temperature[#11]

Three times the speed

- MagnetOs MIS achieves graft placement 3x faster than traditional, funnel-based delivery methods[2]

Engineered for optimal handling

- MagnetOs MIS ensures easy, controlled and precise graft positioning – even in narrow, hard to reach spaces[2]
- Stays reliably in place after implantation[5]
- Resists irrigation and minimizes migration[5]



Kuros Biosciences

Treating difficult-to-fuse patients: 94.4% fusion in high-risk patients undergoing TLIFs[12]

A retrospective, human clinical study evaluated MagnetOs as a standalone graft in 20 patients undergoing single or multi-level MIS and open transforaminal lumbar interbody fusions (TLIFs).

The study demonstrated 94.4% (34/36) of the levels treated were classified as fused by an independent, blinded radiologist at 12-14 months postoperatively.

94.4%
of levels fused

20 patients
underwent
TLIFs

MagnetOs
standalone

Majority of
patients had
comorbidities

Patients with comorbidites

The majority of patients included in this study had comorbidities, including obesity, smoking, prior spine surgery or diabetes.



Justin Davis, MD, FAANS, Assistant Professor, Neurosurgery, The University of Kansas Health System, Kansas City, KS.
20 patients total (17 MIS TLIFs, 3 open TLIFs). Implanted 1.1 - 3.3cc (average 2.0cc) of MagnetOs Easypack Putty per level. MagnetOs Easypack Putty is the same formulation as MagnetOs MIS.

MagnetOs success in MIS TLIF: Case example from the study[13]

A 73-year-old male diagnosed with lumbar stenosis and mobile spondylolithesis causing claudication and radiculopathy. This patient had significant comorbidities including coronary artery disease, obesity, congenital adrenal insufficiency, hypogonadism and Vitamin D deficiency.

Pre-operative MRIs demonstrated degenerative disc disease diagnosis of L4-L5.



The patient underwent a L4-L5 MIS TLIF using MagnetOs Easypack Putty standalone with a titanium expandable cage, supported by pedicle screws.¶

One-year post-operative CT scans reveal complete bridging bone and consolidation of MagnetOs in the intervertebral disc space.



Kuros Biosciences

Ready to extend your reach in MIS?

MagnetOs MIS ordering information:

Product code	Description
703-060-US	Delivery System Kit 5cc (1 delivery dispenser + 5cc cartridge)
703-061-US	Refill Cartridge 5cc

Precision in motion:
See for yourself how **MagnetOs** MIS delivers

Click here or scan the QR-code to watch the video

* Results from in vivo or in vitro laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit kurosbio.com.
† 19 of initial 100 patients were active smokers.
‡ Radiographic fusion data of the smoker subgroup were not statistically analyzed as a subgroup and were not included in the peer-reviewed publication of the study.[1]
§ MagnetOs is not cleared by the FDA as an osteoinductive bone graft.
¶ When used in intervertebral body fusion procedures, MagnetOs MIS must be used with an intervertebral body fusion device cleared by FDA for use with a bone void filler.
# Ambient temperature (max. 45°C/113°F).

References: 1. Stempels, et al. *Spine*. 2024;49(19):1323-1331. **2.** Data on file. MagnetOs MIS. **3.** Duan, et al. *eCM*. 2019;37:60-73. **4.** Van Dijk, et al. *eCM*. 2021;41:756-73. **5.** Data on file. MagnetOs Putty and MagnetOs Easypack Putty. **6.** Van Dijk, LA. 24th SGS Annual Meeting (SwissSociety of Spinal Surgery). Basel, Switzerland. Aug 2024. **7.** Instructions for Use (IFU) MagnetOs Granules (US). **8.** Instructions for Use (IFU) MagnetOs Putty (US). **9.** Instructions for Use (IFU) MagnetOs Easypack Putty (US). **10.** Instructions for Use (IFU) MagnetOs Flex Matrix (US). **11.** Instructions for Use (IFU) MagnetOs MIS (US). **12.** Davis, J. et al. *Orthopedic Review*. 2025. **13.** Data on file. Dr. Davis case study.

Manufactured by **Kuros Biosciences BV**

Prof Bronkhorstlaan 10, Building 48, 3723 MB Bilthoven, The Netherlands
MagnetOs and NeedleGrip are trademarks of Kuros Biosciences

kurosbio.com
cs@kurosbio.com

MAT-0039 August '25

MAGNETOS for predictable fusions

Kuros Biosciences